Condition
Apathy
ClinicalTrials.gov condition label
Clinical trials
33 shownSafety and Tolerability of IRL757 in Participants With Parkinson's Disease and ApathyNCT07461220 · 2026-02-18
RECRUITINGCombined Brain Stimulation and Methylphenidate Treatment for Apathy in DementiaNCT07279740 · 2026-01-01
RECRUITINGTargeting Network Dysfunction in Apathy of Late-life Depression Using Digital TherapeuticsNCT05877885 · 2025-09-19
RECRUITINGRespiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's DiseaseNCT07118956 · 2025-05-01
RECRUITINGLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.NCT06482554 · 2024-06-01
RECRUITINGTargeting Apathy With Music in Parkinson's DiseaseNCT05505019 · 2022-02-09
RECRUITINGVC/VS for Apathy in PDNCT06991335 · 2025-09-01
NOT_YET_RECRUITINGA Randomized Double-Blind Active-Controlled Crossover Trial of Respiratory-Gated Versus Non-Gated Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Motor and Non-Motor Symptoms in Parkinson's DiseaseNCT06642454 · 2024-10-01
ENROLLING_BY_INVITATIONStratifying Psychoses for Personalized REpetitive TMS in Persistent NEgative Symptoms AlleviationNCT06184165 · 2024-03-01
NOT_YET_RECRUITINGMethylphenidate for Apathy in Veterans With Parkinson's DiseaseNCT05669170 · 2024-01-01
NOT_YET_RECRUITINGCognitive Stimulation TherapyNCT05808530 · 2023-05-01
COMPLETEDEffect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.NCT05182151 · 2022-07-29
TERMINATEDStudy of the Effectiveness of Mental Contrasting and Implementation Intention in the Management of Apathy in SchizophreniaNCT04781179 · 2022-02-22
UNKNOWNMotive-specific Intervention for Negative Symptoms in SchizophreniaNCT04793438 · 2021-01-01
UNKNOWNMove to Improve Physical Activity in Parkinson's DiseaseNCT04051151 · 2019-08-26
COMPLETEDAssessment of Apathy in a Real-life Situation, With a Video and Sensors-based SystemNCT03272230 · 2017-09-06
COMPLETEDEvolution of Hypodopaminergic Syndrome in Early Parkinson's DiseaseNCT03141944 · 2017-02-23
COMPLETEDApathy in Dementia Methylphenidate Trial 2NCT02346201 · 2016-01-01
COMPLETEDRepetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's DementiaNCT02190084 · 2014-05-01
COMPLETEDRepetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's DiseaseNCT01885806 · 2013-06-01
UNKNOWNEvaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center StudyNCT01765257 · 2013-06-01
UNKNOWNRole of Mesocorticolimbic Pathway in Apathy of Patients With Parkinson's Disease. - Study Using Diffusion Tensor Imaging and Fibres TrackingNCT01794195 · 2013-02-01
COMPLETEDExploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.NCT01825577 · 2012-11-01
TERMINATEDNon Motors Aspects in De Novo Parkinson's DiseaseNCT02786667 · 2012-06-01
UNKNOWNApathy in SchizophreniaNCT01689181 · 2012-06-01
COMPLETEDEffects of Transcranial Direct Current Stimulation on the Apathy of Alzheimer's DiseaseNCT01481558 · 2012-01-01
COMPLETEDApathy in Dementia Methylphenidate Trial (ADMET)NCT01117181 · 2010-06-01
COMPLETEDThe Role of Apathy in Glycemic ControlNCT00844090 · 2009-07-01
COMPLETEDStudy of Rivastigmine to Treat Parkinsonian Apathy Without DementiaNCT00767091 · 2009-03-01
COMPLETEDImproving Function, Quality of Life, Glycemia in Diabetics With DementiaNCT00792662 · 2008-11-18
WITHDRAWNRole of Apathy in the Effectiveness of Weight Loss InterventionsNCT00548652 · 2007-08-01
COMPLETEDMethylphenidate for Apathy in Alzheimer's Dementia: A Controlled StudyNCT00495820 · 2007-08-01
COMPLETEDTreatment of Apathy in Alzheimer's Disease With ModafinilNCT01172145 · 2005-07-01
COMPLETEDCommon interventions
PlaceboDRUG8MethylphenidateDRUG5Active RAVANSOTHER1AZILECT®DRUG1CM-IIBEHAVIORAL1Cognitive and Behavioral experimental tasksBEHAVIORAL1Cognitive Stimulation TherapyBEHAVIORAL1Deep Brain StimulationDEVICE1Diffusion tensor imaging and fibres trackingBEHAVIORAL1ECOCAPTUREBEHAVIORAL1GameficiationBEHAVIORAL1General Cognitive Training InterventionBEHAVIORAL1ICM_APATHY_TASKSBEHAVIORAL1intermittent theta burst stimulation (iTBS)DEVICE1IRL757DRUG1Istradefylline 40 mgDRUG1Lumateperone 42 mgDRUG1Magnetic Stimulator Magstim Rapid 2DEVICE1medical crisis councellingBEHAVIORAL1Methylphenidate (MPH)DRUG1methylphenidate or placeboDRUG1methyphenidateDRUG1ModafinilDRUG1Motive-specific interventionBEHAVIORAL1MOVEBEHAVIORAL1
Leading sponsors
Anhui Medical University2Institut National de la Santé Et de la Recherche Médicale, France2Johns Hopkins Bloomberg School of Public Health2University Hospital, Clermont-Ferrand2University Hospital, Grenoble2AdventHealth1Brown University1Central Arkansas Veterans Healthcare System1Federal University of Minas Gerais1Hasan Kalyoncu University1Integrative Research Laboratories AB1Louisiana State University Health Sciences Center Shreveport1Medical University of South Carolina1Nora Vanegas1Ralph H. Johnson VA Medical Center1
Trial status mix
COMPLETED15
RECRUITING6
UNKNOWN5
NOT_YET_RECRUITING3
TERMINATED2
ENROLLING_BY_INVITATION1
WITHDRAWN1
Phase mix
NA14
PHASE26
PHASE35
PHASE45
PHASE11
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.